PE20110217A1 - DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS - Google Patents

DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Info

Publication number
PE20110217A1
PE20110217A1 PE2011000111A PE2011000111A PE20110217A1 PE 20110217 A1 PE20110217 A1 PE 20110217A1 PE 2011000111 A PE2011000111 A PE 2011000111A PE 2011000111 A PE2011000111 A PE 2011000111A PE 20110217 A1 PE20110217 A1 PE 20110217A1
Authority
PE
Peru
Prior art keywords
protein
propionamide
pyrrolidin
oxo
ethyl
Prior art date
Application number
PE2011000111A
Other languages
English (en)
Inventor
Mark G Charest
Christine Hiu-Tung Chen
Zhuoliang Chen
Miao Dai
Feng He
Huangshu Lei
Ly Luu Pham
Sushil Kumar Sharma
Christopher Sean Straub
Rung-Ming David Wang
Fang Yang
Leigh Zawel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20110217A1 publication Critical patent/PE20110217A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS TALES COMO: (S)-N-((S)-1-CICLOHEXIL-2-{(S)-2-[4-(4-FLUORO-BENZOIL)-5-METIL-OXAZOL-2-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA; (S)-N-((S)-1-CICLOHEXIL-2-{(S)-2-[4-(2,4-DIFLUORO-BENZOIL)-TIAZOL-2-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA; (S)-N-((S)-1-CICLOHEXIL-2-{(S)-2-[4-(1H-INDOL-2-CARBONIL)-TIAZOL-2-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE PROTEINAS DE APOPTOSIS (IAP) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS COMO EL CANCER
PE2011000111A 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS PE20110217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83500006P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
PE20110217A1 true PE20110217A1 (es) 2011-04-01

Family

ID=38686647

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2011000114A PE20110224A1 (es) 2006-08-02 2007-07-26 PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
PE2011000112A PE20110218A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2007000978A PE20080951A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000111A PE20110217A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2011000113A PE20110220A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PE2011000114A PE20110224A1 (es) 2006-08-02 2007-07-26 PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
PE2011000112A PE20110218A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE2007000978A PE20080951A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011000113A PE20110220A1 (es) 2006-08-02 2007-07-26 DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Country Status (42)

Country Link
US (3) US8552003B2 (es)
EP (3) EP2537846B1 (es)
JP (1) JP4875749B2 (es)
KR (2) KR101087878B1 (es)
CN (2) CN102558165B (es)
AR (3) AR062159A1 (es)
AU (1) AU2007281230B2 (es)
BR (1) BRPI0714803B8 (es)
CA (1) CA2658525C (es)
CL (1) CL2007002234A1 (es)
CR (2) CR10567A (es)
CU (2) CU23866B1 (es)
DK (1) DK2051990T3 (es)
DO (1) DOP2013000084A (es)
EA (2) EA021671B1 (es)
ES (2) ES2405947T3 (es)
GE (1) GEP20115251B (es)
GT (2) GT200900019A (es)
HK (2) HK1176613A1 (es)
HN (1) HN2009000214A (es)
HR (1) HRP20130373T1 (es)
IL (3) IL196596A (es)
JO (1) JO2848B1 (es)
MA (1) MA30652B1 (es)
ME (1) ME00585A (es)
MX (1) MX2009001212A (es)
MY (1) MY150460A (es)
NI (2) NI200900008A (es)
NO (1) NO342230B1 (es)
NZ (1) NZ574393A (es)
PA (1) PA8740901A1 (es)
PE (5) PE20110224A1 (es)
PL (1) PL2051990T3 (es)
PT (1) PT2051990E (es)
SI (1) SI2051990T1 (es)
SM (1) SMP200900013B (es)
SV (1) SV2009003160A (es)
TN (1) TN2009000034A1 (es)
TW (1) TWI408133B (es)
UA (1) UA95485C2 (es)
WO (1) WO2008016893A1 (es)
ZA (1) ZA200900371B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048927A1 (es) 2004-04-07 2006-06-14 Novartis Ag Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
CN103083644B (zh) 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
KR20080067357A (ko) 2005-10-25 2008-07-18 에게라 쎄라퓨틱스 인코포레이티드 Ｉａｐ ｂｉｒ 도메인 결합 화합물
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7985735B2 (en) 2006-07-24 2011-07-26 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
RU2009118487A (ru) * 2006-10-19 2010-11-27 Новартис АГ (CH) Органические соединения
KR20090083412A (ko) * 2006-11-28 2009-08-03 노파르티스 아게 급성 골수성 백혈병의 치료를 위한 ｉａｐ 억제제의 용도
AU2007325280B2 (en) * 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
CA2671607A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
JP5368428B2 (ja) 2007-04-30 2013-12-18 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
AU2009246347A1 (en) 2008-05-16 2009-11-19 Dana Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011016576A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Alanine derivatives as inhibitors of apoptosis proteins
WO2011019782A1 (en) * 2009-08-11 2011-02-17 Novartis Ag Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
KR20120048008A (ko) * 2009-08-12 2012-05-14 노파르티스 아게 아폽토시스 단백질의 억제제의 고체 경구 제제 및 결정질 형태
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
PL2611797T3 (pl) * 2010-08-31 2017-05-31 Hanmi Science Co., Ltd. Pochodne chinoliny lub chinazoliny o aktywności wywoływania apoptozy wobec komórek
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
WO2013010092A1 (en) 2011-07-13 2013-01-17 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
JP2014528409A (ja) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
KR20150023445A (ko) * 2012-05-22 2015-03-05 에프. 호프만-라 로슈 아게 치환된 다이피리딜아민 및 이의 용도
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
JP6523251B2 (ja) 2013-05-01 2019-05-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途
EP3682873B1 (en) 2013-06-25 2024-06-12 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for use in the treatment of persistent hiv infection
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
SG11201706756VA (en) 2015-03-10 2017-09-28 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
BR112018071408A2 (pt) 2016-04-20 2019-02-05 Glaxosmithkline Ip Dev Ltd “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
JP6899993B2 (ja) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
AU2018241944A1 (en) 2017-03-31 2019-08-15 Boehringer Ingelheim International Gmbh Anticancer combination therapy
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CA3066774A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
US20220096436A1 (en) 2019-01-17 2022-03-31 Debiopharm International S.A. Combination product for the treatment of cancer
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
AU2020256220A1 (en) 2019-04-04 2021-09-16 Dana-Farber Cancer Institute, Inc. CDK2/5 degraders and uses thereof
BR112021023229A2 (pt) 2019-05-20 2022-05-31 Servier Lab Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CA3151770A1 (en) 2019-09-25 2021-04-01 Silvano BRIENZA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
TW202210499A (zh) 2020-06-03 2022-03-16 德商百靈佳殷格翰國際股份有限公司 編碼CD80胞外域Fc融合蛋白之重組桿形病毒
IL303079A (en) 2020-11-24 2023-07-01 Novartis Ag Antibody-drug conjugates inhibiting MCL-1 and methods of using them
CN116615252A (zh) 2020-11-24 2023-08-18 诺华股份有限公司 抗cd48抗体、抗体药物缀合物及其用途
EP4288434A1 (en) 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
JPS59141547A (ja) * 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
TR200200767T1 (tr) 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US20020160975A1 (en) * 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
EP1519918A1 (en) 2002-07-02 2005-04-06 Novartis AG Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ATE415413T1 (de) * 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
WO2005049853A2 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
CA2553871A1 (en) * 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
SE527038C2 (sv) * 2004-02-26 2005-12-13 Ingenjoers N Per Oskar Persson Kassett och apparat för vätskefrysning
AU2005218555B2 (en) * 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
AR048927A1 (es) * 2004-04-07 2006-06-14 Novartis Ag Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa
CA2570321C (en) 2004-07-02 2013-10-08 Genentech, Inc. Inhibitors of iap
EA019420B1 (ru) * 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
US20060218632A1 (en) * 2005-03-28 2006-09-28 Cisco Technology, Inc.; Method and system for installing premise equipment
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
WO2008073306A1 (en) * 2006-12-07 2008-06-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN102558165B (zh) 2014-08-13
UA95485C2 (uk) 2011-08-10
CL2007002234A1 (es) 2008-06-13
ME00585B (me) 2011-12-20
WO2008016893A1 (en) 2008-02-07
CN101511860B (zh) 2013-05-01
CU24004B1 (es) 2014-06-27
CR20140555A (es) 2015-01-14
NZ574393A (en) 2012-03-30
AR062159A1 (es) 2008-10-22
MA30652B1 (fr) 2009-08-03
CA2658525C (en) 2013-02-19
PE20110218A1 (es) 2011-04-01
US20140004101A1 (en) 2014-01-02
SMAP200900013A (it) 2009-05-11
HN2009000214A (es) 2011-10-11
BRPI0714803B8 (pt) 2021-05-25
CN102558165A (zh) 2012-07-11
ES2405947T3 (es) 2013-06-04
KR20090038479A (ko) 2009-04-20
CU20110027A7 (es) 2011-12-28
US20110065726A1 (en) 2011-03-17
EP2537850A1 (en) 2012-12-26
GT200900019AA (es) 2015-11-24
IL236883A0 (en) 2015-03-31
PT2051990E (pt) 2013-05-10
DK2051990T3 (da) 2013-05-13
KR101087878B1 (ko) 2011-11-30
EA201401247A1 (ru) 2015-07-30
GEP20115251B (en) 2011-07-11
ES2559042T3 (es) 2016-02-10
SMP200900013B (it) 2010-01-19
TWI408133B (zh) 2013-09-11
HK1127616A1 (en) 2009-10-02
PE20110220A1 (es) 2011-04-11
AR112816A2 (es) 2019-12-18
MX2009001212A (es) 2009-02-11
SV2009003160A (es) 2010-04-13
CA2658525A1 (en) 2008-02-07
AU2007281230A1 (en) 2008-02-07
US8546336B2 (en) 2013-10-01
EP2537846A1 (en) 2012-12-26
PA8740901A1 (es) 2009-04-23
EP2051990B1 (en) 2013-02-06
NO342230B1 (no) 2018-04-23
DOP2013000084A (es) 2013-06-15
EP2537846B1 (en) 2015-09-16
NI200900081A (es) 2010-01-07
TN2009000034A1 (en) 2010-08-19
PE20080951A1 (es) 2008-09-11
IL196596A (en) 2014-09-30
JP2009545613A (ja) 2009-12-24
US20130005663A1 (en) 2013-01-03
US8552003B2 (en) 2013-10-08
EP2051990A1 (en) 2009-04-29
CU23866B1 (es) 2013-03-27
MY150460A (en) 2014-01-30
PL2051990T3 (pl) 2013-07-31
ZA200900371B (en) 2009-12-30
CU20090017A7 (es) 2011-03-21
SI2051990T1 (sl) 2013-06-28
EA200900227A1 (ru) 2009-08-28
AR110313A2 (es) 2019-03-13
CR10567A (es) 2009-02-18
GT200900019A (es) 2010-06-01
KR101245945B1 (ko) 2013-03-22
KR20110030667A (ko) 2011-03-23
BRPI0714803B1 (pt) 2021-03-09
HK1176613A1 (en) 2013-08-02
PE20110224A1 (es) 2011-04-05
IL231079A0 (en) 2014-03-31
IL231079A (en) 2015-02-26
CN101511860A (zh) 2009-08-19
EA021671B1 (ru) 2015-08-31
HRP20130373T1 (en) 2013-05-31
ME00585A (en) 2011-12-20
BRPI0714803A2 (pt) 2013-05-21
NI200900008A (es) 2010-01-07
AU2007281230B2 (en) 2011-09-08
IL196596A0 (en) 2009-11-18
JO2848B1 (en) 2014-09-15
TW200815399A (en) 2008-04-01
NO20090878L (no) 2009-04-27
JP4875749B2 (ja) 2012-02-15

Similar Documents

Publication Publication Date Title
PE20110217A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CL2008001304A1 (es) Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
PA8852901A1 (es) Inhibidores de proteina cinasa
CL2009001160A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
CL2008000899A1 (es) Compuestos derivados de 3-imidazolil-indolilo, inhibidores de la interaccion entre p53 y mdm2 y/o mdm4; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades proliferativas.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
PE20081187A1 (es) Combinaciones de inhibidores de ang2 y vegf
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.

Legal Events

Date Code Title Description
FC Refusal